Teva Pharmaceutical Industries Ltd. (TEVA)

11.35
0.16 1.39
NYSE : Health Technology
Prev Close 11.51
Open 11.76
Day Low/High 11.26 / 11.88
52 Wk Low/High 6.07 / 13.76
Volume 12.78M
Avg Volume 12.06M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 13.33B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Here’s What Jim Cramer Thinks About Consolidation in Pharma and Health Care

Here’s What Jim Cramer Thinks About Consolidation in Pharma and Health Care

Jim Cramer expects to see more deal activity in the pharmaceuticals space.

Jim Cramer Says Investors Should Own Allergan, Shares are Undervalued

Jim Cramer Says Investors Should Own Allergan, Shares are Undervalued

Jim Cramer says investors should own Allergan because the stock is undervalued.

9 Health Names to Like Amid the Rhetoric

9 Health Names to Like Amid the Rhetoric

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

2 Potential Targets of Allergan's Cash Influx

2 Potential Targets of Allergan's Cash Influx

After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."

All Eyes on Allergan and Potential Targets

All Eyes on Allergan and Potential Targets

After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."

Allergan's Outlook Brightens as Generics Sale Seems on Track

Allergan's Outlook Brightens as Generics Sale Seems on Track

A research note confirms that its generics sale to Teva will go ahead.

Charts Say a Swing Trade's Setting Up in Teva

Charts Say a Swing Trade's Setting Up in Teva

I'm focused more on the secondary technicals here rather than the price.

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Cramer: Bulls Defy Reasons to Stampede in Retreat

Cramer: Bulls Defy Reasons to Stampede in Retreat

Downgrades and Allergan's government woes could have inspired panic, but that didn't happen, and that's a sign of strength.

In All This, Allergan's Fundamentals Are Being Ignored

In All This, Allergan's Fundamentals Are Being Ignored

The arbitrage-driven exodus provides investors with a rare opportunity.

The Valeant Saga Triggers Buying Opportunities in Biotech Stocks

The Valeant Saga Triggers Buying Opportunities in Biotech Stocks

Other companies have suffered following the debacle.

Valeant Triggers Buying Opportunities

Valeant Triggers Buying Opportunities

Other companies have suffered following the debacle.

Biotech Bloodbath Brings Up Value

Biotech Bloodbath Brings Up Value

I continue to add to my holdings incrementally. 

Jim Cramer Says Stanley Black and Decker Going to $110 a Share

Jim Cramer Says Stanley Black and Decker Going to $110 a Share

TheStreet's Jim Cramer says Verizon VZ is a stock to hold onto, thanks to its great yield and accelerating growth.

Markets Open Higher, But Eagle Pharma Tanks

Markets have opened slightly higher this morning, with some stocks worth calling out. Las Vegas Sands (LVS) is continuing its recent winning streak, as Macquarie boosted outlook for companies that operate casinos in the Chinese gambling hub of Macau...

Don't Rely on the Luck of the Irish When Picking Sectors and Stocks

Don't Rely on the Luck of the Irish When Picking Sectors and Stocks

It's better to broaden your exposure to avoid seeing your portfolio suffer.

Silly Season Continues for Biotech

Silly Season Continues for Biotech

Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.

Allergan Has a Lot to Gain in Pfizer, Teva Deals

Allergan Has a Lot to Gain in Pfizer, Teva Deals

Management convincingly addressed questions around its pending merger as well as the sale of its generic business.

Generic Drug ETF Offering Portfolio Cure

Generic Drug ETF Offering Portfolio Cure

With biotech stocks getting smashed on the stock market and big pharma getting hammered on the presidential campaign trail, generic drug stocks look awfully appealing.

Antitrust Watchdog: Usual Merger Fix Won't Help Teva's Allergan Deal

Antitrust Watchdog: Usual Merger Fix Won't Help Teva's Allergan Deal

The American Antitrust Institute has taken a stand against Israel-based Teva Pharmaceuticals' $40.5 billion deal to acquire the generics operation of Allergan.

2 Great Biopharma Plays for a Shaky Market

2 Great Biopharma Plays for a Shaky Market

Mylan and Endo International look like bargains at current prices.

Teva, Biomarin Offer Convertible Opportunities Says MainStay Manager

Teva, Biomarin Offer Convertible Opportunities Says MainStay Manager

The convertible bond market has been fairly flat in 2015, closely following the slim returns seen in equities.

6 Dowdy Drug Stocks to Consider for 2016

6 Dowdy Drug Stocks to Consider for 2016

History indicates pharmaceutical companies with low multiples offer payoffs down the road.

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

6 Bullish Charts for the Thankful Investor

6 Bullish Charts for the Thankful Investor

They are a diverse group that could work well as a basket.

Hold on to Your Allergan Shares After the Merger With Pfizer

Hold on to Your Allergan Shares After the Merger With Pfizer

The combined company will provide lots of opportunities.

2 Safe and Cheap Health Care Stocks

2 Safe and Cheap Health Care Stocks

These two will continue to churn out earnings growth.

Allergan Is a Winner -- With or Without Pfizer Deal

Allergan Is a Winner -- With or Without Pfizer Deal

We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.

Stocks Open Higher, But Will Profit-Takers Win?

Markets were slightly up on the open, but I wouldn't be surprised to see some profit-taking today after Wall Street started November with two big days of gains. Jim Cramer made a good point on CNBC this morning about what Allergan (AGN) can and can'...

3 Health Care Names With Healthy Outlooks

3 Health Care Names With Healthy Outlooks

AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.